Vasoactive intestinal peptide-induced prolactin release in hypothyroid patients.
VIP is an established prolactin-releasing factor. VIP gene expression at the anterior pituitary level and the central nervous system is regulated by thyroid hormones. On the other hand, primary hypothyroidism leads in many cases to amenorrhea, galactorrhea and hyperprolactinemia. In this study we assessed prolactin responses to VIP (75 micrograms iv infusion over 12 min) in a group of six hypothyroid women (mean age +/- SE, 38.8 +/- 3.3 yr; serum TSH levels, mU/L, 116.3 +/- 23.9), before treatment and after normalization of thyroid hormone levels during thyroxine (T4) replacement therapy (100-150 micrograms/day over 12-16 weeks). Furthermore, we assessed if VIP infusion had any effects on serum GH levels in these patients. In hypothyroid women, VIP infusion increased serum prolactin concentrations with peak levels being attained at 15 min (28.8 +/- 3.4 micrograms/L). The Area Under the Curve (AUC) was 1921 +/- 103 micrograms/L/2h. PRL responses to VIP were unchanged after T4 therapy, both in terms of peak levels (28.7 +/- 2.2 micrograms/L, NS) and of AUC (2079 +/- 261 micrograms/L/2h, NS). Serum GH levels were unaffected by VIP administration. In conclusion our study shows that, in hypothyroid patients, restoration of normal thyroid hormone levels by thyroxine replacement therapy does not affect lactotroph responsiveness to VIP. Therefore, our data do not support the hypothesis that VIP might contribute to the hypothyroid-induced hyperprolactinemia seen in man.
Valcavi
R
R
2a Divisione di Medicina Interna, Modulo di Endocrinologia, Arcispedale S. Maria Nuova, Reggio Emilia, Italy.
Zini
M
M
Dieguez
C
C
Portioli
I
I
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D005498:Follicular Phase; D013006:Growth Hormone / Q000097:blood; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007037:Hypothyroidism / Q000097:blood* / Q000188:drug therapy; D008875:Middle Aged; D011388:Prolactin / Q000097:blood*; D013963:Thyroid Hormones / Q000097:blood; D013974:Thyroxine / Q000627:therapeutic use; D014660:Vasoactive Intestinal Peptide / Q000009:adverse effects / Q000494:pharmacology*
D013963:Thyroid Hormones; D014660:Vasoactive Intestinal Peptide; D011388:Prolactin; D013006:Growth Hormone; D013974:Thyroxine